Skip to main content
Article thumbnail
Location of Repository

Growth Patterns in the First Three Years of Life in Children with Classical Congenital Adrenal Hyperplasia Diagnosed by Newborn Screening and Treated with Low Doses of Hydrocortisone

By W. Bonfig, H. Schmidt and H. P. Schwarz

Abstract

Background: Linear growth is the best clinical parameter for monitoring metabolic control in classical congenital adrenal hyperplasia (CAH). Objective: To analyze growth patterns in children with CAH diagnosed by newborn screening and treated with relatively low doses of hydrocortisone during the first year of life. Patients and Methods: 51 patients (27 females) were diagnosed with classical CAH by newborn screening. All patients were treated with relatively low doses of hydrocortisone (9-15 mg/m(2) body surface area). 47 patients were additionally treated with fludrocortisone. Results: At birth, height SDS (H-SDS) was 1.1 +/- 1 in girls and 0.9 +/- 1.5 in boys. After 3 months, H-SDS decreased to 0.4 +/- 0.9 in girls and to 0.1 +/- 1.3 in boys. Over the 3-year period, H-SDS further decreased to -0.4 +/- 1.8 in girls and to -0.8 +/- 1 in boys and approached the genetic height potential (target H-SDS of girls -0.5 +/- 0.3 and target H-SDS of boys -0.9 +/- 0.7). During the first 9 months of age, growth velocity was slightly decreased in girls (18.2 +/- 1.9 cm) and boys (17.3 +/- 1.6 cm) when compared to a healthy reference population (girls 19.0 +/- 3.9 cm and boys 18.7 +/- 4.7 cm). At the age of 3 years, bone age was appropriate for chronological age in both girls (2.7 +/- 0.5 years) and boys (2.9 +/- 0.5 years). Conclusion: Birth length is above average in children with classical CAH, which might be the result of untreated hyperandrogenism in utero. With relatively low doses of hydrocortisone treatment, growth velocity decreases slightly during the first 9 months and H-SDS then approaches the genetic height potential. Copyright (C) 2010 S. Karger AG, Basel

Topics: Medizin, ddc:610
Publisher: Ludwig-Maximilians-Universität München
Year: 2011
OAI identifier: oai:epub.ub.uni-muenchen.de:16697
Provided by: Open Access LMU

Suggested articles

Citations

  1. (1998). 4 d e Z e g h e r F , F r a n c o i s I , B o e h m e r
  2. ar gi t ai G , S o l y o m J , B a tt e lin o T , Le b l
  3. (2006). BJ: Absence of increased height velocity in the first year of life in untreated children with simple virilizing congenital adrenal hyperplasia.
  4. (1995). Body mass index reference curves for the UK. Arch Dis Child
  5. (1989). C: Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta
  6. (2002). CAH Working Group: Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology.
  7. (1998). Congenital adrenal hyperplasia – a continuum of disorders. Lancet
  8. (1990). Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
  9. (2006). De Luca F: Birth length and weight in congenital adrenal hyperplasia according to the different phenotypes.
  10. (1993). de Sanctis C: Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
  11. Early growth is not increased in untreated moderately severe
  12. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol
  13. GB: A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
  14. (1999). Khosla S: Androgen effects on bone metabolism: recent progress and controversies.
  15. (1999). Khosla S: Effects of androgens on the insulin-like g r o w t h f a c t o r s y s t e m i n a n a n d r o g e n - r e -sponsive human osteoblastic cell line. Endocrinol
  16. (1998). Khosla S: Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line.
  17. (1959). Radiographic Atlas of S k e l e t a l D e v e l o p m e n t o f t h e H a n d a n d Wrist, ed 2. Palo Alto,
  18. (2003). vant Hof MA: Growth inhibition by glucocorticoid treatment in salt-wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty.
  19. (1997). Voutilainen R: Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatr Res
  20. (2003). White PC: Congenital adrenal hyperplasia.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.